Core Viewpoint - The Hong Kong innovative drug sector is experiencing a significant downturn, with the Hang Seng Innovative Drug Index dropping by 0.84%, influenced by disappointing earnings reports from leading companies and profit-taking activities after substantial prior gains [1][2][4]. Group 1: Market Performance - The Hang Seng Innovative Drug Index has declined from a peak of 4132 points on July 30 to 3820 points, representing a cumulative drop of 7.5% [2][3]. - Leading stocks such as Hutchison China MediTech (00013.HK) fell nearly 16%, with Zai Lab (09688.HK) and WuXi AppTec (06821.HK) both dropping over 10% [1][2]. - The index had previously surged over 150% from a low of 1524 points on April 19 to its peak [3]. Group 2: Earnings Reports - Hutchison China MediTech reported total revenue of $278 million, a year-on-year decrease of 9.16%, despite a net profit increase of 1663.32% due to asset sales [5]. - Zai Lab's total revenue was approximately $216 million, a year-on-year increase of 15.35%, but its core product revenue fell by 8.89% [5]. - Analysts noted that both companies' earnings were below industry expectations, contributing to negative market sentiment [5]. Group 3: Market Sentiment and External Factors - The recent downturn is attributed to a combination of disappointing earnings and profit-taking after a rapid increase in stock prices, with the Hang Seng Innovative Drug Index rising by 30.26% from July 2 to July 29 [6]. - External factors, such as potential U.S. tariffs on imported drugs, have created market anxiety, although the actual impact on the innovative drug sector is expected to be limited [7]. - Despite the current downturn, analysts remain optimistic about the long-term prospects of the innovative drug sector, citing upcoming supportive policies and the ongoing globalization of innovative drug companies [8].

Market Overview - On August 8, the total trading volume of the Shanghai and Shenzhen stock markets was 1.71 trillion yuan, a decrease of 115.3 billion yuan compared to the previous trading day [1] - Sectors that saw significant gains included Xinjiang, rail transit equipment, wind power equipment, and gas, while sectors such as AI, semiconductors, and internet e-commerce experienced declines [1] Top Gainers - Notable stocks with significant gains included: - Guojijinggong (国机精工) with a rise of 9.99% [2] - Huaguang Huaneng (华光环能) up by 10.02% [2] - Rihai Intelligent (日海智能) increased by 10.00% [2] - Hongtong Gas (洪通燃气) rose by 10.03% [2] - Other notable mentions include Liangxin Co. (良信股份) and Jishi Media (吉视传媒) with gains of 9.96% and 10.20% respectively [2] Trading Dynamics - The top three net purchases on the trading leaderboard were: - Shanhe Intelligent (山河智能) with a net purchase of 3.30 billion yuan [5] - Chutianlong (楚天龙) with 2.70 billion yuan [5] - Deen Precision (德恩精工) with 1.34 billion yuan [5] - The top three net sales were: - Kailaiying (凯莱英) with 1.80 billion yuan [6] - Yonyou Network (用友网络) with 1.72 billion yuan [6] - Beiwai Technology (北纬科技) with 1.43 billion yuan [6] Sector Performance - High-performing stocks included: - Guojijinggong (国机精工) with a trading volume of 39.46 billion yuan and a turnover rate of 24.77% [20] - Shanhe Intelligent (山河智能) with a trading volume of 46.39 billion yuan and a turnover rate of 26.26% [20] - Conversely, stocks like Dingjie Smart (鼎捷数智) saw a significant decline of 15.99% with a trading volume of 30.01 billion yuan [20] Institutional Activity - Institutional net purchases were led by: - Guojijinggong (国机精工) with 1.58 billion yuan [7] - Shanhe Intelligent (山河智能) with 1.57 billion yuan [26] - The top net sales by institutions included: - Yingweike (英维克) with 1.95 billion yuan [8] - Kailaiying (凯莱英) with 1.88 billion yuan [8] Notable Stocks and Their Concepts - Shanhe Intelligent (山河智能) is associated with the Yaxia hydropower concept and shield tunneling machines [22] - Chutianlong (楚天龙) focuses on social security cards, digital currency, and cross-border payments [13] - Deen Precision (德恩精工) is involved in robotics, military, commercial aerospace, and AI applications [20]

Summary of Key Points Core Viewpoint - The 2024 A-share Secretary Data Report indicates that the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan, highlighting the significant role of secretaries in connecting investors and listed companies [1][2]. Group 1: Overall Salary and Demographics - The total salary for A-share listed company secretaries in 2024 is 4.086 billion yuan, with an average annual salary of 754,300 yuan [1]. - Among the secretaries, those aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1]. - The educational background of secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1]. Group 2: Industry-Specific Salary Insights - The average annual salary for secretaries in the pharmaceutical and medical service sector is 839,200 yuan [2]. - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2]. - The top three highest-paid secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2].

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the medical and healthcare services sector is 839,200 yuan [2] - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2] - The top three highest-paid company secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2] Age and Education Distribution - Company secretaries aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1] - The educational background of company secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1] - Among the doctoral degree holders, there are 7 individuals, with the only full-time doctoral company secretary in the industry being Cao Nai'en from Huaxia Eye Hospital [1]

Core Insights - The innovative drug industry is experiencing robust growth, with the innovative drug index rising by 50.2% year-to-date as of August 7 [1] - The China National Medical Products Administration approved 43 innovative drugs in the first half of the year, a 59% increase year-on-year, nearing the total of 48 for the entire year of 2024 [2] - The industry is seeing a shift towards deeper strategic collaborations in overseas licensing, moving from simple product exports to comprehensive partnerships [4] Industry Growth and Trends - The innovative drug sector is benefiting from ongoing drug review reforms and policy incentives, leading to a revitalization of the capital market [2] - Companies like Tigermed are establishing integrated platforms to support clinical research across all stages globally [2] - The R&D expenditure of Shijiazhuang Pharmaceutical Group has increased from 1.583 billion HKD in 2018 to approximately 5.19 billion HKD in 2024, reflecting a consistent double-digit growth [2] International Expansion - In the first half of the year, upfront payments for overseas licensing of innovative drugs exceeded 2.5 billion USD, with total transaction amounts nearing 50 billion USD, comparable to the previous year's figures [4] - Shijiazhuang Pharmaceutical Group has completed four overseas licensing agreements this year, with a total contract value of approximately 9.7 billion USD [4] - The potential for sustainable business development (BD) partnerships depends on the core capabilities of Chinese innovative drug companies [4] AI in Drug Development - AI technology is significantly transforming drug development by shortening research cycles and reducing costs, with applications expanding rapidly [7] - The integration of AI with automation in production processes is expected to enhance quality and reduce costs, promoting sustainable practices [7] - Companies like De Rui Zhi Yao are leveraging AI to drive new drug development, with several innovative drugs already in clinical stages [7][8]

Group 1 - The stock price of Kailaiying is reported at 107.20 yuan, down by 2.58 yuan from the previous trading day, with a trading volume of 89,625 hands and a transaction amount of 973 million yuan, resulting in a turnover rate of 2.83% [1] - Kailaiying is a pharmaceutical research and development service company, focusing on innovative drug R&D production services, formulation R&D production services, and clinical research services, operating within the healthcare services sector [1] - The Chief Operating Officer of Kailaiying, Zhang Da, stated that Chinese pharmaceutical companies are forming innovative competitiveness with higher efficiency and lower costs, predicting that more global blockbuster drugs will emerge from China in the next 5 to 10 years [1] Group 2 - In the first half of 2025, the overseas business development (BD) transaction amount of Chinese pharmaceutical companies reached 60 billion USD, surpassing the total amount for the entire year of 2024 [1] - On August 7, Kailaiying experienced a net outflow of main funds amounting to 169.57 million yuan, accounting for 0.5% of its circulating market value, with a cumulative net outflow of 463.88 million yuan over the past five days, representing 1.36% of its circulating market value [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 董事會會議日期 凱萊英醫藥集團（天津）股份有限公司（「本公司」）董事會（「董事會」）謹此公佈， 董事會會議將於2025年8月25日（星期一）舉行，藉以（其中包括）考慮及批准本公 司及其附屬公司截至2025年6月30日止六個月之中期業績及其發佈，並考慮建議 派發股息（如有）。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，2025年8月7日 於本公告日期，本公司董事會由董事長兼執行董事Hao Hong博士，執行董事楊蕊 女士、張達先生及洪亮先生，非執行董事Ye Song博士及張婷女士，以及獨立非 執行董事孫雪嬌博士、侯欣一博士及謝維愷先生組成。 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 董事會會議日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，2025年8月7日 於本公告日期，本公司董事會由董事長兼執行董事Hao Hong博士，執行董事楊蕊 女士、張達先生及洪亮先生，非執行董事Ye Song博士及張婷女士，以及獨立非 執行董事孫雪嬌博士、侯欣一博士及謝維愷先生組成。 凱萊英醫藥集團（天津）股份有限公司（「本公司」）董事會（「董事會」）謹此公佈， 董事會會議將於2025年8月25日（星期一）舉行，藉以（其中包括）考慮及批准本公 司及其附屬公司截至2025年6月30日止六個月之中期業績及其發佈，並考慮建議 派發股息（如有）。 ...

Group 1 - The company has elected Mr. HAO HONG as the Chairman of the Board, with a term starting from the approval date until the current board's term ends [1] - Mr. HAO HONG has been appointed as the Chief Executive Officer (CEO) of the company, effective from the board's approval date until the current board's term ends [1] - Ms. YANG RUI has been appointed as the Co-Chief Executive Officer (Co-CEO), effective from the board's approval date until the current board's term ends [1] - Mr. ZHANG DA has been appointed as both Chief Operating Officer (COO) and Chief Financial Officer (CFO), effective from the board's approval date until the current board's term ends [1] - Mr. CHENGYI CHEN has been appointed as the Chief Technology Officer (CTO), effective from the board's approval date until the current board's term ends [1] - Mr. XINHUI HU has been appointed as the Chief Business Officer (CBO), effective from the board's approval date until the current board's term ends [1] Group 2 - The company has appointed Mr. HONG LIANG, Mr. CHEN ZHAOYONG, and Mr. JIANG YINGWEI as Executive Vice Presidents (EVP), effective from the board's approval date until the current board's term ends [2] - Mr. ZHOU YAN and Mr. XU XIANGKE have been appointed as Senior Vice Presidents (SVP), effective from the board's approval date until the current board's term ends [2] - Mr. XU XIANGKE has been appointed as the Company Secretary, effective from the board's approval date until the current board's term ends [2] - The board has appointed Mr. XU XIANGKE and Mr. ZHENG CHENGJIE as Joint Company Secretaries, effective from the board's approval date until the current board's term ends [2] - Mr. YU CHANGLIANG has been appointed as the Securities Affairs Representative to assist the Company Secretary, effective from the board's approval date until the current board's term ends [2]

凯莱英（002821）(06821)公布，经全体董事一致同意，选举HAO HONG先生为公司第五届董事会董事 长，任职期限自本次董事会审议通过之日起至本届董事会届满止。 公司董事会根据董事长提名，同意聘任HAO HONG先生为公司首席执行官(CEO)，任职期限自董事会审 议通过之日起至本届董事会届满止。 公司董事会根据首席执行官提名，同意聘任杨蕊女士为公司联席首席执行官(Co-CEO)，任职期限自董 事会审议通过之日起至本届董事会届满止。 公司董事会根据首席执行官提名，同意聘任张达先生为公司首席运营官(COO)、首席财务官(CFO)，任 职期限自董事会审议通过之日起至本届董事会届满止。 公司董事会根据首席执行官提名，同意聘任CHENGYI CHEN先生为公司首席技术官(CTO)，任职期限 自董事会审议通过之日起至本届董事会届满止。 公司董事会根据首席执行官提名，同意聘任XINHUI HU先生为公司首席商务官(CBO)，任职期限自董事 会审议通过之日起至本届董事会届满止。 公司董事会根据首席执行官提名，同意聘任洪亮先生、陈朝勇先生、姜英伟先生为公司执行副总裁 (EVP)，任职期限自董事会审议通过之日起至本届董事 ...